Skip to content

NGAL Evaluation Along with B-type Natriuretic Peptide in Acutely Decompensated HF

NGAL Evaluation Along with B-type Natriuretic Peptide in Acutely Decompensated HF - GALLANT

Status
Active, not recruiting
Phases
Phase 2
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON31941
Enrollment
25
Registered
2008-12-15
Start date
2008-08-01
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

decompensatio cordis Heart-failure

Interventions

None listed

Sponsors

BIOSITE Incorporate
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: (Males or females 18 years of age or older) Patients with symptoms of new or decompensated heart failure and who will be treated with at least one dose of IV diuretic Ability to draw blood samples

Exclusion criteria

Exclusion criteria: Acute myocardial infarction or active ischemia Cardiogenic shock or other clinical conditions contraindicate administration of IV diuretic History of marked renal insufficiency (serum creatinine >3.0 mg/dL), on dialysis or in imminent need of dialysis at enrollment

Design outcomes

Primary

MeasureTime frame
The primary objective of this study is to assess the utility of the Triage NGAL Test - in conjunction with the Triage BNP test- as an aid in the early risk assessment for heartfailure- related adverse clinical outcomes (deaths, readmissions, and additional emergent outpatient visits) through Day 30 and Day 90 in patients presenting with acutely decompensated heart failure.

Secondary

MeasureTime frame
The secondary objective is to assess the utility of the Triage NGAL Test as an aid in the early risk assessment for renal dysfunction in patients with acutely decompensated heart failure undergoing treatment with IV diuretics.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)